Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

More Markets

See all Markets

Luke Kawa

Google to reportedly invest up to $40 billion in Anthropic

Amazon announced plans to deepen its investment in the Claude developer earlier this week.

Luke Kawa2h

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

Intel massive stock move after Q1 earnings report

Intel soars by the most in decades after crushing Q1 earnings

A pretty good day.

Matt Phillips3h

Luke Kawa3h

The chip rally is getting so intense, even Qualcomm gets to surge

If you’re a good host, even the last person who shows up to the party gets to have a good time.

On that note, beleaguered Qualcomm — the worst-performing member of the Philadelphia Semiconductor Index this year — is staging a furious rally on Friday, with the industry poised to deliver its 18th consecutive session of gains.

Intel’s earnings are buoying the semi space broadly on Friday, and Qualcomm isn’t being left out. Options activity is also elevated and tilted toward the bull side. As of 9:56 a.m. ET, more than 48,000 calls have changed hands, roughly double its full-day average for the past 20 sessions. Its put/call ratio of 0.17 is well below the 20-day average of 0.44.

The San Diego-based firm has been negative in 2026 since the seventh session of the year, and even with today’s advance, remains mired in the red year to date. The stock cratered after reporting Q1 earnings in early February because its poor Q2 guidance seemingly confirmed fears that smartphone sales would come under pressure from rising memory chip prices and limited availability. Smartphone chips are still Qualcomm’s primary business, accounting for nearly two-thirds of revenues in its most recent quarter, and memory chip sellers appear to be incentivized to meet demand from major AI customers first.

Qualcomm reports Q2 earnings next Wednesday, but that release will likely be overshadowed by the four Magnificent 7 hyperscalers releasing results after the close.

Matt Phillips5h

Analysts applaud Intel’s massive Q1

Intel’s massive Q1 numbers and mega Q2 guidance shocked Wall Street and sent shares across the semiconductor industry higher Friday morning.

Here’s how Wall Street analysts are characterizing the far better-than-expected results:

DA Davidson (rating: “neutral,” price target: $77): “Strong 1Q26 earnings that were highlighted by a significant beat on top and bottom-line expectations. Results in the quarter reflect the growing importance of CPUs and advanced packing. We view the recent Terafab announcement as a proof point that Intel is likely to see continued customer acquisition as the United States demands more domestic semiconductor manufacturing.”

Barclays (rating: “equal weight,” price target: $65): “The sizable top-line and gross margin beat caught us by surprise as our expectation was for tight supply in Q1. Mgmt expects the supply situation to improve through the year and for yields to improve, which should support growth in server.”

HSBC (rating: “buy,” price target: $100): “The market has been
underestimating Intel’s CPU average selling price upside as well as its ability to re-allocate its own foundry capacity to unlock further CPU unit growth, considering a CPU shortage environment that we expect to persist until 2027e.”

Bernstein: (rating: “market perform,” price target: $65): “Server strength seems demonstrably real, client seems to be holding up for now, commentary around 18A/14A was positive, and there remains hopes for forthcoming packaging announcements. That being said, there were quite a few nuggets for the bears as well; namely while 18A yields are seemingly running better than expected they apparently remain underwhelming, and ASP increases are being met by cost inflation.”

JPMorgan (rating: “underweight,” price target: $45): “EPS quality issues, 2H gross margin headwinds, structural OpEx creep, and a Foundry breakeven timeline that is likely to push beyond YE CY27 keep us at UW even as we raise estimates.”

Intel crushes Q1 earnings expectations, forecasts strong Q2 revenue, shares soar

DA Davidson (rating: “neutral,” price target: $77): “Strong 1Q26 earnings that were highlighted by a significant beat on top and bottom-line expectations. Results in the quarter reflect the growing importance of CPUs and advanced packing. We view the recent Terafab announcement as a proof point that Intel is likely to see continued customer acquisition as the United States demands more domestic semiconductor manufacturing.”

Barclays (rating: “equal weight,” price target: $65): “The sizable top-line and gross margin beat caught us by surprise as our expectation was for tight supply in Q1. Mgmt expects the supply situation to improve through the year and for yields to improve, which should support growth in server.”

HSBC (rating: “buy,” price target: $100): “The market has been
underestimating Intel’s CPU average selling price upside as well as its ability to re-allocate its own foundry capacity to unlock further CPU unit growth, considering a CPU shortage environment that we expect to persist until 2027e.”

Bernstein: (rating: “market perform,” price target: $65): “Server strength seems demonstrably real, client seems to be holding up for now, commentary around 18A/14A was positive, and there remains hopes for forthcoming packaging announcements. That being said, there were quite a few nuggets for the bears as well; namely while 18A yields are seemingly running better than expected they apparently remain underwhelming, and ASP increases are being met by cost inflation.”

JPMorgan (rating: “underweight,” price target: $45): “EPS quality issues, 2H gross margin headwinds, structural OpEx creep, and a Foundry breakeven timeline that is likely to push beyond YE CY27 keep us at UW even as we raise estimates.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.